WO2004011632A3 - Oligodendrocyte production from multipotent neural stem cells - Google Patents

Oligodendrocyte production from multipotent neural stem cells Download PDF

Info

Publication number
WO2004011632A3
WO2004011632A3 PCT/CA2003/001151 CA0301151W WO2004011632A3 WO 2004011632 A3 WO2004011632 A3 WO 2004011632A3 CA 0301151 W CA0301151 W CA 0301151W WO 2004011632 A3 WO2004011632 A3 WO 2004011632A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
neural stem
multipotent neural
oligodendrocyte
oligodendrocyte production
Prior art date
Application number
PCT/CA2003/001151
Other languages
French (fr)
Other versions
WO2004011632A2 (en
Inventor
Samuel Weiss
Original Assignee
Stem Cell Therapeutics Inc
Samuel Weiss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Therapeutics Inc, Samuel Weiss filed Critical Stem Cell Therapeutics Inc
Priority to JP2004523706A priority Critical patent/JP4783013B2/en
Priority to CA002492542A priority patent/CA2492542A1/en
Priority to US10/523,253 priority patent/US7704737B2/en
Priority to AU2003250697A priority patent/AU2003250697B2/en
Priority to EP03771036A priority patent/EP1549740A2/en
Publication of WO2004011632A2 publication Critical patent/WO2004011632A2/en
Publication of WO2004011632A3 publication Critical patent/WO2004011632A3/en
Priority to AU2008203234A priority patent/AU2008203234A1/en
Priority to US12/698,757 priority patent/US20100135968A1/en
Priority to US13/424,065 priority patent/US20120189575A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1808Epidermal growth factor [EGF] urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/202IL-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2033IL-5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Abstract

This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
PCT/CA2003/001151 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells WO2004011632A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2004523706A JP4783013B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from pluripotent neural stem cells
CA002492542A CA2492542A1 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
US10/523,253 US7704737B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
AU2003250697A AU2003250697B2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
EP03771036A EP1549740A2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells
AU2008203234A AU2008203234A1 (en) 2002-07-30 2008-07-21 Oligodendrocyte production from multipotent neural stem cells
US12/698,757 US20100135968A1 (en) 2002-07-30 2010-02-02 Oligodendrocyte Production From Multipotent Neural Stem Cells
US13/424,065 US20120189575A1 (en) 2002-07-30 2012-03-19 Oligodendrocyte Production from Multipotent Neural Stem Cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39919202P 2002-07-30 2002-07-30
US60/399,192 2002-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/698,757 Division US20100135968A1 (en) 2002-07-30 2010-02-02 Oligodendrocyte Production From Multipotent Neural Stem Cells

Publications (2)

Publication Number Publication Date
WO2004011632A2 WO2004011632A2 (en) 2004-02-05
WO2004011632A3 true WO2004011632A3 (en) 2004-04-15

Family

ID=31188551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001151 WO2004011632A2 (en) 2002-07-30 2003-07-30 Oligodendrocyte production from multipotent neural stem cells

Country Status (6)

Country Link
US (3) US7704737B2 (en)
EP (2) EP2095823A1 (en)
JP (1) JP4783013B2 (en)
AU (2) AU2003250697B2 (en)
CA (1) CA2492542A1 (en)
WO (1) WO2004011632A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435949B2 (en) 2004-02-13 2013-05-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
JP3984959B2 (en) * 2002-03-27 2007-10-03 株式会社Gbs研究所 Method for inducing proliferation of neural stem cells
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2007036033A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
WO2018093681A1 (en) * 2016-11-15 2018-05-24 Neuralstem, Inc. Multipotent neural stem cells that express platelet derived growth factor (pdgf) receptor and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US5506117A (en) 1989-10-18 1996-04-09 Cytokinetics, Inc. Biochemical process for growing living cells by measuring the amount of nutrient added to the reaction medium
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
EP0768090A3 (en) * 1990-07-18 1997-06-18 Takeda Chemical Industries Ltd Polypeptides having c-AMP producing activity for the prevention of neuronal cell death
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU2489992A (en) 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5623050A (en) 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
PT664832E (en) * 1992-10-16 2002-12-31 Neurospheres Holdings Ltd REMIELINIZATION USING NEURAL ESTAMINAL CELLS
CA2175992C (en) * 1993-11-09 2008-04-01 Samuel Weiss In situ modification and manipulation of stem cells of the central nervous system
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
US6242563B1 (en) * 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
DE19917505A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
EP1185552A1 (en) * 1999-06-16 2002-03-13 Myelos Corporation Retro-inverso peptides derived from interleukin-3
US7160724B2 (en) 2000-03-09 2007-01-09 University Of South Florida Human cord blood as a source of neural tissue for repair of the brain and spinal cord
DE60120682D1 (en) 2000-04-12 2006-07-27 Philadelphia Children Hospital THERAPEUTIC USE OF MESENCHYMAL CURRENT COSTS
US6673606B1 (en) * 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
DE10033219A1 (en) 2000-07-07 2002-01-24 Univ Heidelberg Use of granulocyte colony stimulating factor as neuroprotective agent, for treating acute ischemia and neurodegenerative diseases
WO2002020766A2 (en) * 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
CA2441434A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
AU2002316201A1 (en) * 2001-06-07 2002-12-16 Quark Biotech, Inc. Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20080286234A1 (en) * 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, DUBOIS T M ET AL: "GRANULOCYTE MACROPHAGE - COLONY STIMULATING FACTOR ( GM - CSF ) IS A FATE DETERMINATION AND DIFFERENTIATION FACTOR FOR NEURAL STEM CELL - GENERATED OLIGODENDROCYTE PRECURSORS ( OLPS ).", XP002267009, Database accession no. PREV200300293880 *
GAGE F H: "Mammalian neural stem cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5457, 25 February 2000 (2000-02-25), pages 1433 - 1438, XP002220467, ISSN: 0036-8075 *
KOHAMA I ET AL: "Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. 1 FEB 2001, vol. 21, no. 3, 1 February 2001 (2001-02-01), pages 944 - 950, XP002267008, ISSN: 1529-2401 *
MCQUALTER J L ET AL: "Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 OCT 2001, vol. 194, no. 7, 1 October 2001 (2001-10-01), pages 873 - 881, XP002267007, ISSN: 0022-1007 *
MEHLER M F ET AL: "Cytokines regulate the cellular phenotype of developing neural lineage species.", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR DEVELOPMENTAL NEUROSCIENCE. 1995 JUN-JUL, vol. 13, no. 3-4, June 1995 (1995-06-01), pages 213 - 240, XP002267006, ISSN: 0736-5748 *
See also references of EP1549740A2 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 329.12 URL - http://sf *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435949B2 (en) 2004-02-13 2013-05-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Also Published As

Publication number Publication date
US20100135968A1 (en) 2010-06-03
JP4783013B2 (en) 2011-09-28
AU2003250697A1 (en) 2004-02-16
CA2492542A1 (en) 2004-02-05
AU2008203234A1 (en) 2008-08-07
JP2005534302A (en) 2005-11-17
US20050244965A1 (en) 2005-11-03
WO2004011632A2 (en) 2004-02-05
US20120189575A1 (en) 2012-07-26
US7704737B2 (en) 2010-04-27
AU2003250697B2 (en) 2008-05-01
EP2095823A1 (en) 2009-09-02
EP1549740A2 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
WO2006018220A3 (en) Method for the production of dihydropteridinones
WO2005063971A3 (en) Definitive endoderm
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2007022529A3 (en) Method of treating inflammatory diseases
WO2005030240A3 (en) Vege-cor vege-d materials and methods for stimulation of neural stem cells
WO2003054189A3 (en) Methods for the transformation of vegetal plastids
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
WO2003051362A3 (en) Polymorphs of clopidogrel hydrogensulfate
WO2005005601A8 (en) Compositions and methods for treating and diagnosing cancer
EP2295555A3 (en) Polypeptides having lipase activity and polynucleotides encodig same
WO2003066847A3 (en) Phytase variants
WO2003018767A3 (en) Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
NO20053206L (en) Process for producing ketocarotenoids in the cultivation of genetically modified organisms.
WO2004113608A3 (en) Airlaid method with an improved through-put rate
WO2004015085A3 (en) Method and compositions relating to 5’-chimeric ribonucleic acids
WO2006061215A3 (en) 2-alkyl-cycloalk(en)yl-carboxamides
WO2004011632A3 (en) Oligodendrocyte production from multipotent neural stem cells
WO2004018694A3 (en) Method for producing ketocarotinoids in genetically modified organisms
WO2007023190A3 (en) Genes involved in asymmetric cell division
WO2004021980A3 (en) Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
WO2002040480A3 (en) Crf receptor antagonists and methods relating thereto
WO2006086773A3 (en) Polyamine analogs as modulators of cell migration and cell motility
WO2004072023A3 (en) Oxathiin carboxamide
EP1736513A4 (en) Dry c.i. pigment red 57:1, dry pigment composition and method for producing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003250697

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2492542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10523253

Country of ref document: US

Ref document number: 2004523706

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003771036

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003771036

Country of ref document: EP